These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3861199)

  • 21. Gamma-vinyl GABA (vigabatrin): relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizure reduction in epileptic children.
    Arteaga R; Herranz JL; Valdizán EM; Armijo JA
    Epilepsia; 1992; 33(5):923-31. PubMed ID: 1396437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled study of oral vigabatrin (gamma-vinyl GABA) in patients with cerebellar ataxia.
    Bonnet AM; Esteguy M; Tell G; Schechter PJ; Hardenberg J; Agid Y
    Can J Neurol Sci; 1986 Nov; 13(4):331-3. PubMed ID: 3465425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
    Soares KV; McGrath JJ; Deeks JJ
    Cochrane Database Syst Rev; 2000; (2):CD000203. PubMed ID: 10796320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy.
    Gram L; Lyon BB; Dam M
    Acta Neurol Scand; 1983 Jul; 68(1):34-9. PubMed ID: 6613525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
    Soares KV; McGrath JJ; Deeks JJ
    Cochrane Database Syst Rev; 2001; (2):CD000203. PubMed ID: 11405955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinguishing akathisia and tardive dyskinesia: a review of the literature.
    Munetz MR; Cornes CL
    J Clin Psychopharmacol; 1983 Dec; 3(6):343-50. PubMed ID: 6139392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathophysiology of tardive dyskinesia.
    Gunne LM; Häggström JE
    Psychopharmacology Suppl; 1985; 2():191-3. PubMed ID: 3858799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specificity of vigabatrin for the GABAergic system in human epilepsy.
    Riekkinen PJ; Pitkanen A; Ylinen A; Sivenius J; Halonen T
    Epilepsia; 1989; 30 Suppl 3():S18-22. PubMed ID: 2767015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Gamma-vinyl GABA and tardive dyskinesia: a single-blind study versus placebo].
    Danion JM; Singer L; Tell G; Schechter P
    Ann Med Psychol (Paris); 1984 Jan; 142(1):101-10. PubMed ID: 6476669
    [No Abstract]   [Full Text] [Related]  

  • 30. Open, double-blind and long-term study of vigabatrin in chronic epilepsy.
    Reynolds EH; Ring HA; Farr IN; Heller AJ; Elwes RD
    Epilepsia; 1991; 32(4):530-8. PubMed ID: 1868811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vigabatrin in epilepsy in mentally retarded patients.
    Matilainen R; Pitkänen A; Ruutiainen T; Mervaala E; Riekkinen P
    Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):113S-118S. PubMed ID: 2757902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and biochemical effects of calcium-hopantenate on neuroleptics-induced tardive dyskinesia.
    Kashihara K; Ebara T; Yamamoto M; Ogawa T; Harada T; Otsuki S
    Folia Psychiatr Neurol Jpn; 1985; 39(2):147-53. PubMed ID: 2866149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clonidine therapy for tardive dyskinesia and related syndromes.
    Nishikawa T; Tanaka M; Tsuda A; Koga I; Uchida Y
    Clin Neuropharmacol; 1984; 7(3):239-45. PubMed ID: 6488198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involuntary movement disorders.
    Still CN
    Neurol Clin; 1984 Feb; 2(1):71-89. PubMed ID: 6239089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
    O'Brien CF; Jimenez R; Hauser RA; Factor SA; Burke J; Mandri D; Castro-Gayol JC
    Mov Disord; 2015 Oct; 30(12):1681-7. PubMed ID: 26346941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lithium carbonate in the treatment of movement disorders. A critical review.
    Yassa R; Ananth J
    Int Pharmacopsychiatry; 1980; 15(5):301-8. PubMed ID: 6114936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tardive dyskinesia in Tourette syndrome.
    Golden GS
    Pediatr Neurol; 1985; 1(3):192-4. PubMed ID: 3880404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonin precursor effects in tardive dyskinesia.
    Nasrallah HA; Smith RE; Dunner FJ; McCalley-Whitters M
    Psychopharmacology (Berl); 1982; 77(3):234-5. PubMed ID: 6812144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic principles in hyperkinetic syndromes].
    Arzumanian AM; Stupa MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 1994; 94(5):32-5. PubMed ID: 7900448
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.
    Richardson MA; Bevans ML; Read LL; Chao HM; Clelland JD; Suckow RF; Maher TJ; Citrome L
    Am J Psychiatry; 2003 Jun; 160(6):1117-24. PubMed ID: 12777270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.